Table IV.

Primary and secondary outcomes

	Discontinuation of RAAS inhibitor (N = 21)	Continuation of RAAS inhibitor (N = 25)	Group difference P-value
Mean score (SD)	6.3 (6.3)	3.8 (2.5)	.598*
Median score (IQR)	3 (1, 11)	3 (3, 4)
Negative binomial (IR)†	2.98 (2.17, 4.10)	1.79 (1.30, 2.46)	IRR (95% CI) = 1.667 (1.060, 2.620) P = .027
Individual components of the endpoint:
Death	2 (9.5)	1 (4.0)	.585
Transfer to ICU for Invasive ventilation	2 (9.5)	1 (4.0)	.585
Transfer to ICU for other indication	1 (4.8)	0 (0.0)	.457
Acute myocardial infarction	3 (14.3)	0 (0.0)	.088
Stroke	0 (0.0)	0 (0.0)	NA
Acute decompensated heart failure	7 (33.3)	1 (4.0)	.016
New onset atrial fibrillation	1 (4.8)	0 (0.0)	.457
Length of stay > 4 days	12 (57.1)	18 (72.0)	.527
Development of acute kidney injury (>40% decline in eGFR or doubling of serum Cr)	1 (4.8)	1 (4.0)	1.000
Urgent intravenous treatment for high blood pressure/hypertensive crisis	0 (0.0)	0 (0.0)	NA
>30% increase in baseline high sensitivity troponin	6 (28.6)	6 (24.0)	.749
>30% increase in baseline BNP	6 (28.6)	6 (24.0)	.749
Increase in baseline CRP >30%	5 (23.8)	4 (16.0)	.711
Lymphocyte count drop >30%	3 (14.3)	5 (20.0)	.710

BNP, brain natriuretic peptides; CRP, c-reactive protein; eGFR, estimated glomerular filtration rate; ICU, intensive care unit; IQR, interquartile range; IR, incidence rate; IRR, incidence rate ratio; RAAS, renin-angiotensin aldosterone system; SD, standard deviation.

Group difference was evaluated using Fisher's exact test unless otherwise stated.

^⁎Group difference was evaluated using Wilcoxon rank-sum test.

^†Incident rate and incident rate ratio presented with 95% confidence interval.